Semustine
Phase 1Small molecule
Merck & Co.Semustine is one of 23 small molecule programs targeting Allogeneic Hematopoietic Stem Cell Transplantation. It is currently in Phase 1.
1
Indications
5
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Allogeneic Hematopoietic Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 3
Nexavar
BayerPhase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
Tepadina
Jazz PharmaceuticalsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Mesenchymal Stromal Cells
Mario Negri Institute for Pharmacological ResearchPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Busulfex
Akero TherapeuticsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Allogeneic Hematopoietic Stem Cell Transplantation2 trials
Outcome1 trial
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Semustine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company